2.
OS and PFS of 1,085 patients with DLBCL according to primary sites of lymphoma
| Primary site | n (%) | 5-year OS (%) | 5-year PFS (%) |
| OS, overall survival; PFS, progression-free survival; N-DLBCL, nodal diffuse large B-cell lymphoma; EN-DLBCL, extranodal diffuse large B-cell lymphoma; CNS, central nervous system. | |||
| N-DLBCL | 679 (62.6) | 65.5 | 57.0 |
| Lymphonodus | 440 (64.8) | 59.8 | 50.0 |
| Waldeyer’s ring | 134 (19.7) | 83.6 | 76.9 |
| Mediastinal | 87 (12.8) | 65.5 | 60.9 |
| Spleen | 18 (2.7) | 72.2 | 61.1 |
| EN-DLBCL | 406 (37.4) | 56.9 | 49.0 |
| Stomach | 91 (22.4) | 70.3 | 64.8 |
| Intestine | 65 (16.0) | 56.9 | 46.2 |
| Nose & sinuses | 36 (8.9) | 69.4 | 58.3 |
| Testis | 34 (8.4) | 38.2 | 35.3 |
| Skin | 32 (7.9) | 43.8 | 40.6 |
| Thyroid | 28 (6.9) | 57.1 | 53.6 |
| CNS | 26 (6.4) | 26.9 | 15.4 |
| Breast | 23 (5.7) | 69.6 | 52.2 |
| Bone | 14 (3.4) | 50.0 | 42.9 |
| Salivary gland | 11 (2.7) | 63.6 | 63.6 |
| Ovarian & cervix | 11 (2.7) | 54.5 | 36.4 |
| Oral cavity | 7 (1.7) | 42.9 | 42.9 |
| Kidney | 7 (1.7) | 42.9 | 42.9 |
| Lung | 6 (1.5) | 66.7 | 33.3 |
| Orbit | 5 (1.2) | 60.0 | 60.0 |
| Other | 10 (2.5) | 68.5 | 47.5 |